The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?

Haematologica. 2019 Feb;104(2):222-225. doi: 10.3324/haematol.2018.206987.

Authors

Antonia M S Müller¹, Shaji K Kumar², Benedetto Bruno³

Affiliations

¹ Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.
³ Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy benedetto.bruno@unito.it.

No abstract available

Publication types

Editorial

MeSH terms

Graft vs Host Disease / etiology
Hematopoietic Stem Cell Transplantation* / adverse effects
Hematopoietic Stem Cell Transplantation* / methods
Humans
Multiple Myeloma / diagnosis
Multiple Myeloma / mortality
Multiple Myeloma / therapy*
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome

Grants and funding

P50 CA186781/CA/NCI NIH HHS/United States